PLX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
19.9M
-41.0%
33.8M
+270.0%
9.1M
-48.9%
17.9M
+14.0%
15.7M
Cost of Revenue
7.8M
+88.1%
4.1M
-10.7%
4.6M
-44.5%
8.3M
+41.8%
5.9M
Gross Profit
12.1M
-59.0%
29.6M
+557.9%
4.5M
-52.7%
9.5M
-2.7%
9.8M
Operating Expenses
7.5M
-12.0%
8.5M
-7.5%
9.2M
+23.9%
7.4M
-14.2%
8.6M
R&D
4.4M
-19.8%
5.4M
-3.7%
5.6M
+26.1%
4.5M
-25.5%
6.0M
SG&A
3.1M
+2.0%
3.1M
-13.5%
3.5M
+20.4%
2.9M
+11.6%
2.6M
Operating Income
4.7M
-77.9%
21.1M
+554.0%
-4658000
-318.6%
2.1M
+81.8%
1.2M
EBITDA
5.1M
-76.4%
21.6M
+604.6%
-4271000
-270.6%
2.5M
+63.4%
1.5M
Net Income
3.8M
-79.4%
18.3M
+432.8%
-5504000
-333.7%
2.4M
+1336.0%
164.0K
EPS (Basic)
$0.05
-78.3%
$0.23
+428.6%
$-0.07
-333.3%
$0.03
$0.00
EPS (Diluted)
$0.05
-77.3%
$0.22
+414.3%
$-0.07
-333.3%
$0.03
$0.00
Shares (Diluted)
82.6M
-0.6%
83.0M
+10.0%
75.5M
-6.6%
80.8M
-0.6%
81.3M
Protalix BioTherapeutics (PLX) โ€” Financials